Global Enteral Feeding Formulas Market - 2020-2027
|經腸營養劑的全球市場:2020年∼2027年 Global Enteral Feeding Formulas Market - 2020-2027|
|出版日期: 按訂單生產||內容資訊: 英文||
The global enteral feeding formulas market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Enteral feeding is delivery of a nutritionally complete feed containing fat, protein, minerals, carbohydrate, water, and vitamins, directly to stomach, duodenum, or jejunum. There are various types of tubes available for enteral feed formula, such as, gastrostomy, nasojejunal tube, nasogastric tube and jejunostomy. These tubes are made of silicon, polyurethane or PVC and are of different length from 30 to 43 inches, with diameters from 8 to 14 inches for adults. Some of the other equipment used for enteral feeding include, administration reservoir (bottle, feed bag, etc.), syringes, and enteral pump. Various routes are used in the administration of the necessary nutrients are cost-effective, healthy and also an alternative choice for the invasive process. Enteral feeding is preferred for patients with malnutrition due to eating disorders such as anorexia nervosa, dysphagia, and stomach infections, among others.
The demand for enteral feeding formula demand is surging with rising therapeutic uses of enteral feeding formula coupled with the introduction of new technologically advanced enteral feeding formula. In addition, the growing geriatric population globally and the rising prevalence of preterm births are also boosting the market growth.
High prevalence rate of chronic disorders is dirving the market growth
Increasing incidences of chronic disorders, such as cardiovascular diseases, cancer, diabetes, and (Coronary Obstructive Pulmonary Disorders) COPD is expected to drive the growth of the enteral feeding formulas market.
As per the International Diabetes Federation, diabetes patients spent US$ 760 billion in 2019, of which, most was spent by Type-1 diabetes patients on insulin drugs. Around 463 million adults (20-79 years) are living with diabetes currently, and by 2045 this is projected to rise to 700 million. The proportion of type 2 diabetes people is increasing in most countries.
Also, as per the American Heart Association, in 2015, approximately 41.5% of the U.S. population was suffering from some form of cardiac disease, it is further estimated that this prevalence is likely to increase to 45% by 2035. According to the Centers for Disease Control and Prevention (CDC) of the U.S., about half of the population (47%) of the United States have at least one of these three risk factors.
For the treatment of these chronic diseases, a longer hospital stay and recovery time is required. Patients face problems in swallowing food, so, external nutrition is given to the patient through the tube. Hence, the increase in the cases of chronic diseases, such as cancer and cardiovascular diseases, are expected to drive the growth of the market over the forecast period.
Lack of reimburesement is hampering the growth of the enteral feeding formulas market
The lack of reimbursement of enteral feeding formula is expected to hamper the usage of enteral feeding formula and lower the adoption rate of the enteral feeding formula in the forecast period.
COVID-19 Impact Analysis
The demand for enteral feeding formulas is growing with the increasing number of COVID-19 cases in hospitals. In 2020, the critical care segment is rapidly growing in the enteral feeding formula industry due to the rising number of the COVID-19 patients, which are also leading the consumption of nutritional feeding formulas more towards the patients with the ventilators.
With growing awareness among the healthcare professionals regarding hospital-associated malnutrition is anticipated to boost the usage rate of enteral feeding formulas in hospitals. Moreover, increasing number of ICU admissions during COVID-19, rising demand for enteral formulations among critically ill patients, is likely to boost the market growth.
The global enteral feeding formulas market is segmented on the basis of product, flow type, stage, application, and end-users.
Oncology segment is expected to hold a major market share in the enteral feeding formulas market
The burden of cancer is growing rapidly worldwide. Cancer is expected to grow rapidly during the forecast period. The WHO has reported that cancer is the second leading cause of death globally and is responsible for 9.6 million deaths in 2018 and worldwide, about 1 in 6 deaths is only because of cancer. Also, around 70% of deaths from cancer occur in low and middle-income countries. WHO stated that around 17.9 million people die each year with cardiovascular diseases, and globally, it accounts for 31% of deaths. Majority of tumour-bearing patients suffer from cancer cachexia, which causes insulin resistance, increased lipolysis with loss of body fat, increased protein turnover, and loss of muscle mass, causing loss of appetite and weight.
Also, there are several complications and side effects in the patients while cancer treatment, including difficulty in chewing and swallowing solid food, mucositis sores in the mouth, altered saliva level, which makes it difficult to swallow. To improve the clinical condition of patients, delivery of nutrition is very difficult for the cancer patients to take the food orally, hence, the nutrition is supplied by enteral feeding tubes to help them maintain the body mass.
Standard formulas segment is expected to hold the largest market share during the forecast period
By product, the market is classified into standard and disease-specific formulas. Among these, the standard formulas segment accounted for the largest market share due to its high demand for enteral nutrition and basic clinical nutrition, high commercial availability, and growing investment by major companies. The standard formulas segment is further segmented into polymeric formulas and monomeric formulas. There are different varieties of standard formulas available with the growing demand for low-cost nutrient formulations. The demand for standard tube feeds is high among volume sensitive patients or patients with congestive heart failure, Syndrome of Inappropriate Diuretic Hormone (SIADH), and renal failure.
On the other hand, the disease-specific formulas are expected to grow at the fastest growth rate during the forecast period, 2020 to 2027 due to growing improvements in enteral feeding formula and devices with rising prevalence of several chronic diseases. Disease-specific formulas segment is further segmented into renal, diabetic, hepatic, pulmonary, and others. With growing awareness among healthcare professionals and patient population towards the benefits of enteral medical foods is one of the major factors driving the segment growth.
By Stage, the Adult Segment held the largest market share in 2019
On the basis of stage, the market is segmented into adults and paediatrics. The adults segment accounted for the largest market share in 2019, due to the growing adoption of tube feed among adults. The enteral feeding can be performed by the syringe method, gravity drip method, and the pump method in adults. According to a study by the Medical Nutrition International Industry, the financial cost associated with malnutrition or undernutrition in the European Union is around US$ 185 billion. About one in six individuals are affected by malnutrition globally. With the growing demand for such nutrition formulations in the adult population is one of the major factors boosting segment growth.
Home care is expected to grow at the fastest growth rate over the forecast period, owing to the rising number of patients receiving home enteral feeding with growing awareness towards balanced nutrition. There is a rise in adoption of enteral feeding formulas among home healthcare patients. A policy was developed in combination with the National Institute for Clinical Excellence (NICE) which has revolutionized the healthcare service for patients on nutrition supplements and has enhanced the service delivery.
North America region holds the largest market share in global enteral feeding formulas market
North America region is dominating the global enteral feeding formulas market accounted for the largest market share in 2019, due to several factors, such as the growing geriatric population, rising prevalence of preterm birth, and the increasing number of chronic disease patients. The United States is the major contributor to the growth of enteral feeding formulas market. In the U.S., it is projected that the number of people aged above 65 years will more than double by 2060. The growing geriatric population would increase the cases of chronic diseases, such as cancer and diabetes, which will lead to an increase in the hospital stay of the patient. Also, according to the WHO, around 15 million babies are born preterm, and this number is rising. Hence, the market is expected to grow further in this region over the forecast period.
Asia-Pacific region is growing at the fastest CAGR during the forecast period.
The Asia Pacific market is expected to grow at the fastest CAGR during the forecast period. The market in Japan, China, and India are likely to grow significantly during the forecast period, due to the large presence of patients suffering from chronic diseases and disorders, increasing incidences of preterm births, growing healthcare expenditure, rapidly developing healthcare infrastructure, and growing demand in these countries.
The enteral feeding formulas market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Fresenius Kabi AG, B. Braun Melsungen AG, Victus, Inc., Hormel Food Corp., Danone S.A., Nestle S.A., Mead Johnson Nutrition Company, Global Health Products, Inc., Meiji Holdings Co., Ltd., Trovita Health Science, among others.
B. Braun Melsungen AG
B. Braun is majorly involved in the manufacturing, marketing and distributing various healthcare products and services in the fields of medical technology, medical services, and pharmaceutical products. The company product range comprises of around 5,000 products of which 95% of the products being manufactured by the company. Some of the major product lines manufactured by the company include disposables required for infusion, nutrition and pain therapy, infusion pumps and systems, surgical instruments, suture materials, hip and knee implants, dialysis equipment and accessories, and stoma and wound care products. B. Braun has presence in 64 countries and develops products in 18 therapy fields of the healthcare industry. The company operates its business through five business divisions which include hospital care, Aesculap, B. Braun Avitum, out-patient market (OPM) and other sales.
Enteroport® plus: Enteral nutrition pump
Accessories Enteroport® plus: Accessories for the enteral nutrition pump Enterport® plus
Nutritub®: Polyurethane feeding tube
Gastric Tubes: Naso-gastric and naso-intestinal PVC tubes for short term use only.
Duodenal Tubes: PVC tube
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Enteral Feeding Formulas market globally. For instance,
The global enteral feeding formulas market report would provide an access to an approx. 77 market data table, 73 figures and 300 pages.
LIST NOT EXHAUSTIVE